Gillinov A Marc, Faber Christiano, Houghtaling Penny L, Blackstone Eugene H, Lam Buu-Khanh, Diaz Ramon, Lytle Bruce W, Sabik Joseph F, Cosgrove Delos M
Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
J Thorac Cardiovasc Surg. 2003 Jun;125(6):1350-62. doi: 10.1016/s0022-5223(02)73274-1.
We sought to compare mitral valve repair and replacement as treatments for degenerative mitral valve disease with coexisting ischemic heart disease. Specifically, we sought to (1) identify differences between patients undergoing repair and replacement, (2) determine whether the choice of mitral valve procedure affected survival after adjusting for those differences, and (3) discover which patients were predicted to benefit from mitral valve repair and which from replacement.
From 1973 to 1999, 679 patients (mean age, 67 +/- 9.1 years; 73% men) with degenerative mitral valve and ischemic heart diseases underwent combined coronary artery bypass grafting and either mitral valve repair (66%) or replacement (34%). Factors associated with repair and replacement were used for multivariable propensity matching. Risk factors for death were identified by means of multivariable, multiphase hazard-function analysis.
Patients more likely to undergo repair had isolated posterior chordal rupture (P <.0001) or more recent date of operation (P <.0001); those more likely to undergo replacement were older (P =.0003) or had bileaflet prolapse (P <.0001). Unadjusted survival at 30 days and 1, 5, and 10 years was 97%, 92%, 79%, and 59% after repair and 94%, 88%, 70%, and 37% after replacement. After adjusting for comorbid factors, the extent and effect of ischemic heart disease, and propensity score, the survival benefit of repair became evident after 2 years (P =.01). Eighty-nine percent of patients were predicted to benefit from repair.
In patients with degenerative mitral valve and ischemic heart diseases, mitral valve repair confers a survival advantage over replacement that becomes evident about 2 years after the operation.
我们试图比较二尖瓣修复术和置换术作为退行性二尖瓣疾病合并缺血性心脏病的治疗方法。具体而言,我们试图(1)确定接受修复术和置换术的患者之间的差异,(2)在对这些差异进行调整后,确定二尖瓣手术的选择是否会影响生存率,以及(3)发现哪些患者预计能从二尖瓣修复术中获益,哪些能从置换术中获益。
1973年至1999年,679例(平均年龄67±9.1岁;73%为男性)患有退行性二尖瓣疾病和缺血性心脏病的患者接受了冠状动脉旁路移植术联合二尖瓣修复术(66%)或置换术(34%)。将与修复术和置换术相关的因素用于多变量倾向匹配。通过多变量、多阶段风险函数分析确定死亡风险因素。
更有可能接受修复术的患者有孤立性后叶腱索断裂(P<.0001)或手术日期更近(P<.0001);更有可能接受置换术的患者年龄较大(P =.0003)或有双叶脱垂(P<.0001)。修复术后30天、1年、5年和10年的未调整生存率分别为97%、92%、79%和59%,置换术后分别为94%、88%、70%和37%。在对合并症因素、缺血性心脏病的程度和影响以及倾向评分进行调整后,修复术的生存获益在术后2年变得明显(P =.01)。89%的患者预计能从修复术中获益。
在患有退行性二尖瓣疾病和缺血性心脏病的患者中,二尖瓣修复术比置换术具有生存优势,这种优势在术后约2年变得明显。